Verona Pharma (VRNA) has shown strong positive momentum recently, driven by analyst upgrades and promising product performance. Multiple analysts have raised their price targets for VRNA, reflecting confidence in the company's growth prospects. Truist raised its target from $57 to $76, while Roth MKM increased it from $68 to $83, signaling a bullish outlook on the stock.
The stock is currently trading at $61.04, with key technical indicators suggesting a bullish trend. The RSI (14) is at 55.25, indicating the stock is not overbought, and the MACD is positive at 2.85, signaling upward momentum. The Stochastic Oscillator shows a bullish crossover with K at 48.77 and D at 60.93, further supporting the positive outlook.
A meeting with Truist on March 10 could act as a catalyst for the stock. Positive news from this meeting may drive further upward momentum, building on the already strong analyst sentiment.
Based on the positive analyst sentiment, strong technical indicators, and upcoming catalysts, the stock is expected to rise to $66.25 in the next trading week. This represents a bullish outlook, making it a good time to buy.
Prediction: Buy VRNA with a target price of $66.25.
The price of VRNA is predicted to go up 8.59%, based on the high correlation periods with GATX. The similarity of these two price pattern on the periods is 97.5%.
VRNA
GATX
Canaccord Genuity
2025-02-12
Price Target
$44 → $72
Upside
+14.83%
Roth MKM
2025-01-10
Price Target
$68
Upside
+50.44%
Wells Fargo
2025-01-08
Price Target
$64 → $74
Upside
+60.17%